# Filing Detail

Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001641172-25-021187
Filing Date
2025-07-28
Accepted
2025-07-28 17:17:42
Documents
11
Period of Report
2025-07-28

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | PRE 14A | formpre14a.htm | PRE 14A | 521358
2 | EX-1 | ex1.htm | EX-1 | 2634
3 | EX-2 | ex2.htm | EX-2 | 79772
4 | EX-3 | ex3.htm | EX-3 | 80473
5 | EX-4 | ex4.htm | EX-4 | 74361
6 | EX-5 | ex5.htm | EX-5 | 74389
7 | EX-6 | ex6.htm | EX-99 | 21467
8 | EX-7 | ex7.htm | EX-7 | 161911
9 | GRAPHIC | formpre14a_001.jpg | GRAPHIC | 3993
10 | GRAPHIC | proxy_001.jpg | GRAPHIC | 322208
11 | GRAPHIC | proxy_002.jpg | GRAPHIC | 171684
| Complete submission text file | 0001641172-25-021187.txt |  | 1667094

Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

EIN.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 000-21617 | Film No.: 251156659
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)